Category Stock Exchange

ProKidney Releases Q1 2026 Financial Results

[ad_1] AlphaStreet Newsdesk powered by AlphaStreet Intelligence PROK|EPS -$0.14|Rev $226,000|Net Loss $42.6M ProKidney Corp. (PROK) reported a wider loss for the first quarter of 2026 as the clinical-stage biotechnology company continues to advance its cell therapy programs for chronic kidney…